Penny M. Heaton

Johnson & Johnson (Singapore) — Singapore

Medicine · Health Sciences

29h-index4.4kcitations55works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Viral gastroenteritis research and epidemiology(33), Viral Infections and Immunology Research(18), Animal Virus Infections Studies(14), Hepatitis Viruses Studies and Epidemiology(12), Respiratory viral infections research(9)

Publications55 total

Successes and Opportunities during the Pandemic: Reflections and Revelations from a Vaccine Development Perspective
Clinical Pharmacology & Therapeutics·2023· 3 citedOpen Access
Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019
Clinical Infectious Diseases·2021· 51 citedOpen Access
Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases
Nature Reviews Drug Discovery·2021· 4 citedOpen Access
Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities
Vaccines·2021· 53 citedOpen Access
Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)
UNC Libraries·2021Open Access
Herd Immunity: The Journey Is as Important as the Destination
The Journal of Infectious Diseases·2021· 6 citedOpen Access
Challenges of Developing Novel Vaccines With Particular Global Health Importance
Frontiers in Immunology·2020· 51 citedOpen Access
The Covid-19 Vaccine-Development Multiverse
New England Journal of Medicine·2020· 154 citedOpen Access
Clinical trials in the pandemic age: What is fit for purpose?
Gates Open Research·2020· 10 citedOpen Access
From Patient to Molecule: In Pursuit of Universal Treatments for TB
Clinical and Translational Science·2019· 1 citedOpen Access
Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)
UNC Libraries·2019Open Access
Why Child Health and Mortality Prevention Surveillance?
Clinical Infectious Diseases·2019· 14 citedOpen Access
Real‐World Data: An Unrealized Opportunity in Global Health?
Clinical Pharmacology & Therapeutics·2019· 10 citedOpen Access
Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study
The Lancet Global Health·2018· 275 citedOpen Access
Preparing Physician-Scientists for an Evolving Research Ecosystem
JAMA·2018· 15 citedOpen Access
Precisely Tracking Childhood Death
American Journal of Tropical Medicine and Hygiene·2017· 35 citedOpen Access
Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries
Vaccine·2015· 61 citedOpen Access
Sa1877 Dynamic Response of Humoral Immunity After Vaccination With a Recombinant Antigen Based Vaccine Against H. pylori in Healthy Volunteers After Infectious Challenge With H. pylori
Gastroenterology·2013· 2 cited
1047 Efficacy of an Investigational Recombinant Antigen Based Vaccine Against a CagA H. pylori Infectious Challenge in Healthy Volunteers
Gastroenterology·2012· 13 cited
Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)
Human Vaccines·2011· 43 cited
page 1 of 3Next →

Frequent Co-authors

Michael J. Dallas(13), Michelle G. Goveia(11), Robbin Itzler(11), Mark J. DiNubile(11), David O. Matson(7), Penelope H. Dennehy(7), H. F. Clark(7), Paul A. Offit(7), Timo Vesikari(6), Pierre Van Damme(6), Joseph F. Heyse(6), Max Ciarlet(6), Leif Gothefors(5), John W. Boslego(5), Zoe Rodriguez(4), Barbara J. Kuter(4), Mathuram Santosham(3), C D C Christie(3), Michele L. Coia(3), Matthew Onorato(3)